Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Dr. Mensen adds that tirzepatide (Mounjaro or Zepbound), a dual GLP-1/GIP agonist, may also be recommended. "Based on the fact that each individual experience with this medication is different ...

It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and SC versions for treating obesity. Per the terms, CordenPharma will ...

VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous ...

to support the commercialization of its oral obesity drug VK2735. The deal covers supply of both the active pharmaceutical ingredient, or API, and the final finished product. Back To Top ...

VK2735 is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, currently in Phase 2 trials for oral dosing and expected to ...

While management assured us of positive developments across various programs in the metabolic disease and rare disease space, there shouldn’t be any doubt that VK2735 should be positioned as the ...

VK2735 is a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor. Viking is testing VK2735 in two formulations, a subcutaneous injection and an oral pill. The company expects ...